|This article needs additional citations for verification. (March 2014)|
|Key people||Harren Jhoti (CEO)
Martin Buckland (CBO)
Astex Therapeutics was a biotechnology company focused on the discovery and development of drugs in oncology and other areas. Astex was founded in 1999 by Sir Tom Blundell, Chris Abell & Harren Jhoti, and is located in Cambridge, England.
The company's research efforts focus on utilization of a proprietary "drug discovery engine" dubbed Pyramid. Astex has also solved the structure of two key cytochrome P450 isoenzymes involved in drug metabolism, 2C9 & 3A4, which the company hopes will help in optimizing the pharmacokinetic properties and safety of their lead compounds.
Astex Therapeutic's first drug candidate, a cell cycle inhibitor, entered Phase I clinical trials in 2005. Since that time they have created eight drugs that have progressed into the clinical stage of development.
- Tim Kelly (5 September 2013). "Japan's Otsuka to buy cancer drug maker Astex Pharma". Reuters.
- Supergen Press Release April 6, 2011 "http://investor.astx.com/releasedetail.cfm?ReleaseID=601567"
- Carr RA, Congreve M, Murray CW, Rees DC (2005) Fragment-based lead discovery: leads by design. Drug Discov Today 10: 987-92.
- Congreve M, Murray CW, Blundell TL (2005) Structural biology and drug discovery. Drug Discov Today 10: 895-907.
- Williams PA, Cosme J, Vinkovic DM, et al. (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone Science 305: 683-86 (available online by registration at Science website)
- Astex Technology: Pioneering Fragment-based Lead Discovery